Zarei Ehsan, Sefidi-Heris Youssof, Saadat Iraj
Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran.
EXCLI J. 2021 Oct 11;20:1488-1498. doi: 10.17179/excli2021-4091. eCollection 2021.
Gastric cancer has a weak prognosis and its usual treatments depend on surgery and chemotherapy. These treatments suffer from some drawbacks such as high rates of local recurrence and metastasis, low survival rates, and significantly decreased life quality. Therefore, new therapeutic methods for improved gastric cancer care with minimal side effects seem necessary. Currently, combinatorial treatments for cancer are preferred and recently, metformin (Met) and curcumin (Cur) have been interesting options for this type of therapy. The aim of the present study was to investigate anticancer effects of metformin and curcumin in both single and combinatorial treatment forms on AGS gastric cancer cell line. In comparison to single treatments with each substance, the results of co-treatments with metformin and curcumin indicated synergistic inhibitory effects on cell viability, wound healing, cell migration and invasion, and primary tumor formation. To determine the selective effect of combination of "Met + Cur" on cancerous cells, very low doses of 8 anticancer drugs (cisplatin, carboplatin, oxaliplatin, epirubicin, doxorubicin, docetaxel, paclitaxel, and methotrexate) used in MTT assay were comparatively tested on AGS cancer cells and normal HDF cells for 48 and 72 hours. The results indicated that the combination of "Met + Cur" significantly increased cytotoxic effects of all anticancer drugs of AGS cells. It is while in normal HDF cells, combination of "Met + Cur" along with anticancer drugs had no effect. This can be inferred as selectively additive effect.
胃癌预后较差，其常规治疗依赖于手术和化疗。这些治疗存在一些缺点，如局部复发和转移率高、生存率低以及生活质量显著下降。因此，似乎有必要采用新的治疗方法来改善胃癌治疗并减少副作用。目前，癌症的联合治疗是首选，最近，二甲双胍（Met）和姜黄素（Cur）成为这类治疗中令人感兴趣的选择。本研究的目的是调查二甲双胍和姜黄素单药及联合治疗形式对AGS胃癌细胞系的抗癌作用。与每种物质的单药治疗相比，二甲双胍和姜黄素联合治疗的结果表明对细胞活力、伤口愈合、细胞迁移和侵袭以及原发性肿瘤形成具有协同抑制作用。为了确定“Met + Cur”组合对癌细胞的选择性作用，在MTT试验中使用的8种抗癌药物（顺铂、卡铂、奥沙利铂、表柔比星、多柔比星、多西他赛、紫杉醇和甲氨蝶呤）的极低剂量在AGS癌细胞和正常HDF细胞上进行了48小时和72小时的比较测试。结果表明，“Met + Cur”组合显著增强了AGS细胞所有抗癌药物的细胞毒性作用。而在正常HDF细胞中，“Met + Cur”与抗癌药物的组合没有效果。这可以推断为选择性相加作用。
